Cabaletta Bio Inc Ordinary Shares CABA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
-
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
-
Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
-
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment
-
Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy
-
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs
-
Cabaletta Bio Gets FDA OK to Study CABA-201 in Generalized Myasthenia Gravis
Trading Information
- Previous Close Price
- $4.64
- Day Range
- $4.28–4.70
- 52-Week Range
- $3.47–26.35
- Bid/Ask
- $4.10 / $5.00
- Market Cap
- $225.19 Mil
- Volume/Avg
- 594,649 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 138
- Website
- https://www.cabalettabio.com
Comparables
Valuation
|
Metric
|
CABA
|
TCRX
|
CCCC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.12 | 1.09 | 1.51 |
Price/Sales | — | 42.87 | 10.98 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CABA
|
TCRX
|
CCCC
|
|---|---|---|---|
Quick Ratio | 11.35 | 7.72 | 4.89 |
Current Ratio | 11.52 | 7.77 | 5.09 |
Interest Coverage | — | −29.80 | −715.67 |
Quick Ratio
CABA
TCRX
CCCC
Profitability
|
Metric
|
CABA
|
TCRX
|
CCCC
|
|---|---|---|---|
Return on Assets (Normalized) | −35.12% | −32.50% | −22.53% |
Return on Equity (Normalized) | −37.84% | −54.73% | −34.97% |
Return on Invested Capital (Normalized) | −41.73% | −39.01% | −30.08% |
Return on Assets
CABA
TCRX
CCCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zpvrxhyfsq | Vlgr | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zlbyqhzzb | Xmnxmn | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lmqgrnmq | Mrhcgzy | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Dsrnfyp | Vhfjdqg | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Ntydvxtjn | Xjpfc | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Tdtrwgs | Dmpyg | $28.3 Bil | |||
| Moderna Inc
MRNA
| Lprrnxxt | Zmk | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qpfmyrvnz | Vmvq | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Tfkpdyt | Mymxm | $13.3 Bil | |||
| Incyte Corp
INCY
| Zrfyyspg | Qxdxvc | $13.0 Bil |
United States